Substance abuse
Drug research and approvals for substance abuse: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 143 studies of substance abuse are recruiting on ClinicalTrials.gov, and Health Canada has authorized 6 drug trials for it since 2013.
- Recruiting worldwide: 143
- Trials authorized in Canada: 6
- FDA orphan approvals: 0
- EU medicines: 0
Newest posted first, of 143 recruiting on ClinicalTrials.gov ↗
- Adaptive Decision Support for Addiction Treatment (ADAPT) Serial Randomized Testing for Usability, Round 3NCT07793383 · Not applicable · Yale University · starts Aug 17, 2026
- Naturally Produced Cannabinoids for Neuroprotection From ConcussionNCT07715864 · Phase 2 · University of Regina · starts Jun 1, 2026
- Cannabis Observations on Brain Waves, Retrieval, and Attention: Experiment 4NCT07679581 · Not reported · L. Cinnamon Bidwell · starts Dec 10, 2025
- Challenging the Endocannabinoid System in Sleep Restricted Healthy Volunteers to Modulate Physiological Arousal…NCT07656350 · Not applicable · King's College London · starts Jun 2, 2026
- Hybrid Dialectical Behavior Therapy for Veterans to Further Reduce Emotion Regulation Problems and Trauma SymptomsNCT07652645 · Not applicable · Arkin · starts Jun 1, 2026
- Improving Jail Response to the Overdose Crisis: A Hybrid Trial of Jail ECHO to Improve MOUD Implementation and Public…NCT07637994 · Not applicable · University of Massachusetts, Worcester · starts Jan 1, 2027
- The Pharmacokinetics of a Hemp-Based Topical ProductNCT07603518 · Phase 1 · Johns Hopkins University · starts May 26, 2026
- Optimizing Pregnancy and Treatment Interventions for Moms 3.0NCT07586917 · Not applicable · University of Utah · starts Jul 10, 2026
- A Unique, Co-Designed Family-Based TherapyNCT07587359 · Not applicable · Ohio State University · starts Jul 14, 2026
Newest first; search them all in Canada trials
| May 14, 2024 | A registered clinical trial of psilocybin-assisted therapy (PAT) for stimulant use disorder: a safety, feasibility and efficacy studyPsilocybin | Filament Health Corp. | Pending |
| Nov 8, 2023 | A phase III, randomized, double-blind, placebo-controlled study to confirm the authenticity of point-of-care urine samples using oral fluorescein sodium in…Fluorescein | Uptru Inc. | Ongoing |
| Mar 26, 2015 | Investigating neuroinflammation response in substance use disorder[18F]-FEPPA inj | Pet Centre Centre for Addiction and Mental Health | Ongoing |
| Feb 12, 2015 | D3 dopamine receptors in substance use disorder: pet studies with [11c]-(+)phno[11C]-(+)-PHNO injection | Pet Centre Centre for Addiction and Mental Health | Ongoing |
| Dec 31, 2014 | Evaluation of pregabalin's abuse liability and effects on benzodiazepine withdrawal symptoms in inpatients undergoing medically-assisted benzodiazepine…Pregabalin | Centre for Addiction and Mental Health | Closed |
| Oct 24, 2013 | Comparing treatments for HIV-infected opioid and alcohol users in an integrated care effectiveness study (CHOICES)Naltrexone | The Regents of The University of California, San Francisco | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA